ストックスクリーナーアプリを入手
39.72
1.20%
0.47
前日終値:
$39.25
開ける：
$39.27
24時間の取引高:
415.25K
Relative Volume:
0.74
時価総額：
$2.31B
収益：
-
当期純損益:
$-146.66M
株価収益率:
-14.42
EPS:
-2.7541
ネットキャッシュフロー:
$-133.21M
1週間 パフォーマンス:
-0.30%
1か月 パフォーマンス:
+30.10%
6か月 パフォーマンス:
-31.51%
1年 パフォーマンス:
-40.23%
1日の値動き範囲:
$38.25
$39.93
1週間の範囲:
$38.25
$41.38
52週間の値動き範囲:
$29.26
$68.21
Apogee Therapeutics Inc Stock (APGE) Company Profile
APGE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
39.72 | 2.31B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2024-11-25 | 開始されました | Canaccord Genuity | Buy |
| 2024-05-10 | 開始されました | BofA Securities | Buy |
| 2023-12-20 | 開始されました | BTIG Research | Buy |
| 2023-08-08 | 開始されました | Guggenheim | Buy |
| 2023-08-08 | 開始されました | Jefferies | Buy |
| 2023-08-08 | 開始されました | Stifel | Buy |
| 2023-08-08 | 開始されました | TD Cowen | Outperform |
| 2023-08-08 | 開始されました | Wedbush | Outperform |
すべてを表示
Apogee Therapeutics Inc (APGE) 最新ニュース
Analysts Set Apogee Therapeutics, Inc. (NASDAQ:APGE) PT at $92.17 - Defense World
Is Apogee Therapeutics (APGE) Among the Best IPO Stocks to Buy in 2025? - Insider Monkey
(APGE) Trading Advice - Stock Traders Daily
Charles Schwab Investment Management Inc. Sells 2,936 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
12 Best IPO Stocks to Buy in 2025 - Insider Monkey
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Bank of New York Mellon Corp Decreases Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
May 16th Options Now Available For Apogee Therapeutics (APGE) - Nasdaq
(APGE) Trading Signals - Stock Traders Daily
Apogee Therapeutics (NASDAQ:APGE) Coverage Initiated at Citigroup - Defense World
Victory Capital Management Inc. Sells 123,296 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Citigroup Initiates Coverage of Apogee Therapeutics (APGE) with Buy Recommendation - Nasdaq
Citigroup Initiates Apogee Therapeutics at Buy With $95 Price Target -March 13, 2025 at 07:14 am EDT - Marketscreener.com
Apogee Therapeutics initiated with a Buy at Citi - TipRanks
Zevra Therapeutics Inc (ZVRA) gets rating Resumed from Cantor Fitzgerald - Knox Daily
Apogee Therapeutics (NASDAQ:APGE) Given Outperform Rating at Wedbush - Defense World
Apogee Therapeutics signs manufacturing deal with Samsung Biologics By Investing.com - Investing.com Canada
Apogee Therapeutics signs manufacturing deal with Samsung Biologics - Investing.com India
Apogee Therapeutics IncEnters Master Services Agreement With Samsung Biologics - Marketscreener.com
TD Cowen reiterates buy on Apogee Therapeutics stock - Investing.com India
TD Cowen reiterates buy on Apogee Therapeutics stock By Investing.com - Investing.com UK
Strong Buy Recommendation for Apogee Therapeutics Driven by Promising Clinical Data and Strategic Pipeline Developments - TipRanks
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial - AOL
Apogee Therapeutics CEO Michael Henderson sells $301,511 in stock By Investing.com - Investing.com South Africa
Apogee Therapeutics CEO Michael Henderson sells $301,511 in stock - Investing.com
Apogee Therapeutics CMO Carl Dambkowski sells $48,463 in stock By Investing.com - Investing.com South Africa
Apogee Therapeutics CMO Carl Dambkowski sells $48,463 in stock - Investing.com India
Q1 EPS Estimates for Apogee Therapeutics Reduced by Wedbush - Defense World
New York State Common Retirement Fund Increases Position in Apogee Therapeutics, Inc. (NASDAQ:APGE) - Defense World
Apogee Therapeutics (NASDAQ:APGE) Reaches New 1-Year Low After Earnings Miss - Defense World
Where are the Opportunities in (APGE) - Stock Traders Daily
Optimistic Buy Rating for Apogee Therapeutics Driven by Promising Clinical Trial Developments - TipRanks
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by Handelsbanken Fonder AB - Defense World
Apogee Therapeutics (NASDAQ:APGE) Receives “Outperform” Rating from Wedbush - Defense World
Apogee Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
APGEApogee Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results - GlobeNewswire
Jefferies lifts Apogee Therapeutics stock target to $86, maintains buy - Investing.com India
Jefferies lifts Apogee Therapeutics stock target to $86, maintains buy By Investing.com - Investing.com South Africa
Apogee Therapeutics price target raised to $116 from $110 at Guggenheim - TipRanks
Apogee Therapeutics Reports Positive Phase 1 Results - TipRanks
Apogee Therapeutics, Inc. Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG990 - Marketscreener.com
Apogee Therapeutics Full-Year Loss Widens -March 03, 2025 at 06:56 am EST - Marketscreener.com
Apogee Therapeutics, Inc. SEC 10-K Report - TradingView
Apogee Therapeutics Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer Trial - Marketscreener.com
Apogee Therapeutics Advances Clinical Pipeline for APG777 and APG279, Reports Strong Cash Position and 2024 Financial Results - Nasdaq
Can Apogee's Overenrolled Clinical Trial Fast-Track Its Challenge to DUPIXENT? - StockTitan
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy - The Bakersfield Californian
Apogee Therapeutics Inc (APGE) 財務データ
収益
当期純利益
現金流量
EPS
Apogee Therapeutics Inc (APGE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| HENDERSON MICHAEL THOMAS | Chief Executive Officer |
Mar 05 '25 |
Sale |
30.15 |
10,000 |
301,511 |
1,292,987 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):